
Smart method to enhance direct drug delivery to uterine fibroid by injection

arlene K. Taylor. Ph.D.







The Goal

Problem

Strategy

Solution

Properties

Results

Interest




he Problem


want to keep my uterus. What are my options?" -Anonymo


The Pro (Uterine Fil



Vary in size








(2-3 x more common)

\$5.9 to \$34.4 billio annually



- Associated with pain, bleeding, and infertility
- Hysterectomy surgery is the only permanent treatment option





Various size problems...need different strategies

Strategy

an we "melt" the fibroid?


Strate (Local Inje

Drug therapies cause systemic side effects
Local injection is viable
Collagenase is a promising candidate

Collagenase injection



Gross examination



Strate (Local Inje

We need to retain the drug long enough to "melt" the fibroid.

Solut


(LiquoG


Solution


an we target therapy directly to the tumor?

Solut


(LiquoG







Delays localized drug release



Releases active collagenase to melt fibroids (48 h)

Free collagenase (48 h)


What is LiquoGel?

Proper

(LiquoG

A copolymeric hydrogel
Stabilized by physical crosslinks
Easy to formulate and produce







Proper

(LiquoG

Thermo-responsive







Propei

(LiquoG

Not Toxic










Prope


(LiquoG







LiquoGel



- ✓ Entraps and releases many drug classes
- ✓ Sustained and localized release for hours
- ✓ Injectable (31G needle)
- √ Forms a stable gel
- ✓ Ends return to the "synthetic tool box" to deliver cocktail therapy mixture

Journal of Functional Biomaterials, 2011, 2(3), 173-194.

Resu (LiquoGe

Sep. 2, 2011

PCT/US2011/050405 filed with US PTO

Taylor, DK; et al J. Functional Biomaterials, 2011, 2(3), 173-194.

May 3, 2013

Filed US Patent Application No. 13/818782

Jun. 10, 2016

Pilot in vitro and in vivo studies conducted in collaboration with BioSpecifics

Aug. 29, 2017

Issued US Patent 9,744,138 - Treatment method and product for uterine fibroids using purified collagenase - Leppert, PC; Wegman, TL; and Taylor, DK

Jan. 1, 2019

Duke/NCCU CTSI Award supported preliminary ex vivo studie

LiquoGel Roadmap

Optimization

Scaled Production

Application

nterest

/ho's expressed interest in this technology?

Uterine Fibroids 2016 ommunity Event A Case for Women's Healt



- What are Fibroids?
- Survivor Stories
- Treatment Options
- Clinical Trial Info


8 AM - 3:30 PMurday, Oct. 8th

MDC, Inc., 307 W Main Street Durham, NC

Registration (includes free lunch) at www.uterinefibroids.Eventbrite.com



Co-sponsored by The Campion Fund and the Delta Sigma Theta Distinguished Endowed Chair.



11 completed survey

Participants' Likelihood of Attending Next Conference

N=	Not at all Likely to Attend	Unlikely to Attend	Not sure if I'll Attend	Somewhat Likely to Attend	Very Likely To Attend	Mean ± S Dev
11	0.0%	0.0%	9.1%	18.2%	72.7%	4.64 ± .6

Participants' Ratings of the Learning Gains as a Result of the Conference

N=	No Gain or Very Small Gain	Small Gain	Moderate Gain	Large Gain	Very Large Gain	Mean ± S Dev
11	0.0%	0.0%	18.2%	63.6%	18.2%	4.00 ± .6

Intere

Captured conference highlights and disseminated by video www.youtube.com (https://youtu.be/bgWLVAWvpRc), www.taylorresearch.org and www.campionfund.org.

Data show that the Year 2 conference was effective in addressing three major areas for participants:

Providing strategies for working with policymakers to advocate for women's health

Learning better ways to support a family member with uterine fibroid

Teaching women's health and workin with OB/GY professionals

Acknowledgements

Phyllis Leppert

Friederike Jayes

Ria Corder

Saad Khan

John Cullen

Robert Vachieri

Sashi Gadhi



